← Search & browse all drugs
CARDIOVASCULAR SYSTEM › PERIPHERAL VASODILATORS › PERIPHERAL VASODILATORS › 2-amino-1-phenylethanol derivatives
isoxsuprine
C04AA01
Forms & Strengths
- Oral tablets: 10 mg
- Oral tablets: 20 mg
Adult Dosing
- Cerebrovascular insufficiency: 10 to 20 mg orally 3 to 4 times daily
- Peripheral vascular disease (Raynaud's, arteriosclerosis obliterans): 10 to 20 mg orally 3 to 4 times daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Adjunctive treatment of cerebral vascular insufficiency
- Adjunctive treatment of peripheral vascular disease associated with arteriosclerosis obliterans, Buerger's disease, and Raynaud's disease
Mechanism of Action
- Direct relaxation of vascular smooth muscle, predominantly within skeletal muscle and cerebral vessels
- Beta-2 adrenergic agonist activity contributing to vasodilation
- Weak alpha-1 adrenergic antagonist properties
Contraindications
- Recent arterial bleeding or hemorrhage
- Hypersensitivity to isoxsuprine or any component of the formulation
- Immediate postpartum period (historical/obsolete indication)
Adverse Reactions
- Hypotension (especially orthostatic)
- Tachycardia and palpitations
- Dizziness, lightheadedness, or weakness
- Nausea, vomiting, gastrointestinal distress
- Skin rash or flushing
Drug Interactions
- Antihypertensive agents: Potential for additive hypotensive effects
- Vasodilators: May potentiate vasodilation and hypotension
- Beta-blockers: May antagonize the beta-2 mediated vasodilatory effects of isoxsuprine
Curated Content: Needs Vetting Before Put to Clinical Use